New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
September 6, 2017 – The FDA announced that Kayexalate (sodium polystyrene sulfonate) drug labels will be updated to state that the dose should be separated by at least 3 hours from other orally administered drugs.
Download PDF
Return to publications
